Drug Trial Radar · NCT04789356
Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity
Last checked: Nov 20, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
6,233
Actual
Start
Mar 18, 2021
Primary completion
Jul 5, 2021
Study completion Mar 2022
Sponsor
- Lead sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira DouradoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Butantan Institute
- First posted
- Mar 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a quasi-experimental study with risk-based allocation. Public security and education professionals from the state government will be included. In the initial evaluation, the presence of comorbidities associated with an increased risk of serious disease due to COVID-19 will be evaluated, according to the national plan for the implementation of vaccination against COVID-19. Those with at least one of these comorbidities will be invited to receive the study vaccine in two doses, with an interval of 28 days (±7 days). Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project. If, after 12 months, the participant in the low-risk group (no vaccine) has not received CoronaVac, or any other vaccine available, he/she will receive the vaccine, exactly as offered in the other group (two doses of CoronaVac with an interval of 28 days - with a tolerance of 7 days before or after). All participants will be followed up for 12 months from inclusion in the study. Immunization is expected to reduce the risk of moderate to severe disease of those with comorbidities to the level of those of the same age group who do not have these comorbidities but face similar occupational risks.
Conditions
- Covid19
Interventions
Adsorbed SARS-CoV-2 (inactivated) vaccineBiological
600 SU/dose; Two doses separated by 28 days (± 7 days). Intramuscular (deltoid) administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence density of moderate and severe clinical cases of COVID-19Time frame: 2 weeks after the second vaccine dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Escola Normal Superior - Universidade do Estado do Amazonas
Manaus, Amazonas, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.